ADARx Pharmaceuticals, Inc. (ADRX)
| Market Cap | 2.01B |
| Revenue (ttm) | 6.13M |
| Net Income | -87.87M |
| EPS | -7.74 |
| Shares Out | 112.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 264,652 |
| Open | 18.22 |
| Previous Close | 18.13 |
| Day's Range | 17.66 - 18.36 |
| 52-Week Range | 16.61 - 23.21 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 34.25 (+90.81%) |
| Est. Earnings | Nov 15, 2026 |
About ADRX
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention wit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ADRX stock is "Strong Buy." The 12-month stock price target is $34.25, which is an increase of 90.81% from the latest price.
News
ADARx Pharmaceuticals initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of ADARx Pharmaceuticals (ADRX) with an Outperform rating and $32 price target
ADARx Pharmaceuticals initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of ADARx Pharmaceuticals (ADRX) with an Overweight rating and $38 price target The firm says the company leverages two technologies to overcome limitations of first-generat...
ADARx Pharmaceuticals initiated with a Buy at TD Cowen
TD Cowen initiated coverage of ADARx Pharmaceuticals (ADRX) with a Buy rating and no price target The company has a combined $200B total addressable market across its complement, orphan, cardio,…
ADARx Pharmaceuticals initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of ADARx Pharmaceuticals (ADRX) with an Overweight rating and $32 price target The company has a “derisked”siRNA platform and “robust” clinical stage pipeline, the an...
ADARx Pharmaceuticals initiated with a Buy at UBS
UBS initiated coverage of ADARx Pharmaceuticals (ADRX) with a Buy rating and $35 price target The firm has conviction in the company’s siRNA platform “with deep and durable target depletion.”…
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
Opening Day: Amaero, Bamboo Insurance postpone IPOs
Amaero and Bamboo Insurance announced that both have postponed their planned IPOs, citing adverse market conditions. LATEST IPOS AND DIRECT LISTINGS: ADARx Pharmaceuticals (ADRX) opened on September 2...
ADARx Pharmaceuticals opens at $22.10, IPO priced at $17 per share
ADARx Pharmaceuticals (ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, priced its upsized initial public offering of 26.25M shares of common stock at ...
ADARx Pharmaceuticals indicated to open at $28, IPO priced at $17
ADARx Pharmaceuticals (ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, priced its upsized initial public offering of 26.25M shares of common stock at ...
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADARx Pharmaceuticals said on Thursday it had raised $446.3 million in an upsized US initial public offering, reflecting growing investor appetite for biotech listings.
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricin...
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADARx Pharmaceuticals is seeking a valuation of up to $1.74 billion in its U.S. initial public offering, the company said on Monday, as investor appetite for biotech listings strengthens.
ADARx Pharmaceuticals IPO Registration Document (S-1)
ADARx Pharmaceuticals has filed to go public with an IPO on the NASDAQ
siRNA biotech ADARx Pharmaceuticals files for a $100 million IPO
ADARx Pharmaceuticals, a Phase 3 biotech developing siRNA therapies for various diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.